DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) - Pipeline Review, H1 2016" report to their offering.
Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) pipeline Target constitutes close to 24 molecules. Out of which approximately 17 molecules are developed by Companies and remaining by the Universities/Institutes.
Metabotropic Glutamate Receptor 5 - Pipeline Review, H1 2016, outlays comprehensive information on the Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) Metabotropic glutamate receptor 5 (mGluR5) is a G protein-coupled receptor. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors.
Signaling activates a phosphatidylinositol calcium second messenger system and generates a calcium activated chloride current. mGluR5 plays an important role in the regulation of synaptic plasticity and the modulation of the neural network activity.
The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 1, 9 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.
Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 5 (mGluR5 or GRM5 or GPRC1E or MGLUR5) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.
- Addex Therapeutics Ltd
- Confluence Pharmaceuticals LLC
- Eisai Co., Ltd.
- Eli Lilly and Company
- Heptares Therapeutics Limited
- Hua Medicine (Shanghai) Ltd.
- Johnson & Johnson
- Medgenics, Inc.
- Merz Pharma GmbH & Co. KgaA
- Novartis AG
- Sumitomo Dainippon Pharma Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/b6mnfc/metabotropic